Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Scaling Community-Clinical Linkage Models to Address Diabetes and Hypertension Disparities in the Southeast United States

20. april 2022 oppdatert av: NYU Langone Health
The purpose of this study is to work with primary care physicians and their staff, and with community health workers (CHWs) to improve diabetes and hypertension management, health behaviors and improve blood pressure for South Asian patients with uncontrolled diabetes and hypertension in primary care clinics in Atlanta, Georgia. The CHWs are community members who are trained to work with patients to address health needs holistically by providing information on wellness, nutrition, stress relief, and blood pressure management in a culturally-appropriate and language-appropriate manner.

Studieoversikt

Status

Fullført

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

The study will provide research training, technical assistance, and capacity-building to community and clinical sites in Georgia for implementation of culturally tailored, evidenced-based CHW programs to improve HTN and diabetes management for South Asians. In addition, the use a multi-theoretical framework to test the effectiveness of a CHW-led intervention compared to usual care among South Asian individuals with diabetes and uncontrolled HTN in Atlanta. The primary outcome is blood pressure control, defined as 130/80 mmHg. It is hypothesized that, compared to usual care, individuals receiving the CHW intervention will be 20% more likely to achieve blood pressure control at 6 months.

And to apply RE-AIM and CFIR frameworks to delineate factors influencing appropriateness, fidelity, adoption, and maintenance of the intervention within clinical and community settings to optimize intervention replication.

In addition, this study will serve as a national information and dissemination resource in the adaptation of evidence-based strategies to reduce geographic disparities in HTN and diabetes across Asian American groups.

Studietype

Intervensjonell

Registrering (Faktiske)

195

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • New York
      • New York, New York, Forente stater, 10016
        • NYU Langone

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

21 år til 75 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

CHW intervention:

Inclusion Criteria:

  • identified as of South Asian ethnicity
  • are at least 21 years of age and younger than age 75
  • had an appointment with a physician or mid-level clinician for routine non-emergent primary care in the last 12 months
  • a diagnosis of diabetes
  • a diagnosis of hypertension
  • an uncontrolled BP reading (>130/80mmHg) in the last 6 months

Provider Surveys Inclusion criteria

  • clinicians employed by the clinic
  • have enrolled into the study.

Key Informant Interviews Inclusion criteria

  • must be a provider, clinic manager, or community health worker.

CHW intervention

Exclusion Criteria:

  • under the age of 21 and older than 75
  • pregnant
  • Type 1 diabetes or diabetes secondary to other conditions
  • malignancy or life threatening illness with life expectancy of <5 years
  • inability to perform unsupervised physical activity
  • diagnosed cognitive deficits or limited decision-making capacity

Provider Surveys Inclusion criteria

  • clinicians who are unable to complete the survey in the English language.

Key Informant Interviews Inclusion criteria

  • who are unable to participate in the interview conducted in the English language.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Community Health Workers (CHW) treatment group
There will be 81 treatment participants who will receive the Community Health Workers (CHW) intervention. Once recruited and consented, surveys will be administered and collected at baseline and 6 months in person or by a study coordinator within two weeks of completion of the CHW coaching component of the intervention. Participants enrolled in the intervention will receive monthly text and phone call reminders. in addition, multiple sessions will be hosted at varying times/days of the week to accommodate schedules of both working individuals and at-home caretakers. Finally, small incentives will be provided at each session to encourage ongoing attendance, and a cash raffle prize will be distributed at program completion for individuals who attend all five sessions.
Participants will undergo 5 group-based health education sessions on hypertension and diabetes management and provide culturally and linguistically tailored health information and resources There will be 2 one-on-one in-person meetings and up to 7 follow-up calls/meetings to engage in goal-setting activities regarding changes to health behaviors, medication adherence, or other issues related to diabetes prevention as identified jointly by patient and CHW. Participants will develop with the CHW and receive a copy of their long-term and short-term Participant Action Plan. Referrals to other services available in the community (i.e. exercise classes, social services, mental health, tobacco cessation, etc.
Ingen inngripen: Control group
There will be 81 control participants who will be offered the health education sessions as a point of service and not for research purposes

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in BP control
Tidsramme: Baseline Visit, 6 months visits
The primary outcome will be the proportion of eligible patients at a practice site to achieve BP control (130/80 mmHg) six months following the index office visit. Individuals receiving care during the implementation of the intervention will be more likely achieve BP control six months following the index office visit than individuals receiving care as usual. The primary outcome of interest is the proportion of patients who achieve BP control. this will be measured by the treatment participants and providers surveys.
Baseline Visit, 6 months visits

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in Hemoglobin A1c (HbA1c)
Tidsramme: 6 months
Change in HbA1c will be measured in participants of CHW intervention versus the control participants. Clinical data will be retrieved from EHR.
6 months
Change in systolic blood pressure (SBP)
Tidsramme: 6 months
Change in SBP will be measured in participants of CHW intervention versus the control participants. Clinical data will be retrieved from EHR.
6 months
Change in diastolic blood pressure (DBP)
Tidsramme: 6 months
Change in DBP will be measured in participants of CHW intervention versus the control participants. Clinical data will be retrieved from EHR.
6 months
Change in body mass index (BMI)
Tidsramme: 6 months
Change in BMI will be measured in participants of CHW intervention versus the control participants. Clinical data will be retrieved from EHR.
6 months
Physicians Attitudes Regarding the Integrated Intervention
Tidsramme: Baseline Visit, 6 months
Physician attitudes will be primarily assessed with data from brief surveys collected from the participating clinicians. Survey items with response scales will be designed to capture data on each of the research questions above. For instance, participants may be asked to respond on a five-point scale (from 1=strongly agree to 5=strongly disagree) to the following statement: "CHWs are helpful tome". The survey data come from a small sample (n=approximately 10) and are only intended to quantify descriptive information and not for extensive statistical analyses. The data will be tabulated and summarized descriptively to assess change in attitudes from baseline to 6 months.
Baseline Visit, 6 months
Barriers and Facilitators to Implementation Adoption and Implications for Scalability
Tidsramme: Baseline Visit, 6 months visit, 12 month visit
At baseline, qualitative interviews of key informants will assess current satisfaction and usage of CHWs and organizational workflows. At follow-up the interviews will assess barriers and facilitators to the implementation and adoption process of the integrated intervention appropriates, fidelity to the interventions and the solicit recommendations for the replication and scalability of the intervention to other sites. Satisfaction and outcomes from the partnership and capacity building process will also be assessed. Audio-recordings and interview transcripts will be stripped of all identifying data. Using a qualitative approach, interview data will be transcribed and analysis will follow "constant comparison" analytic approach. Using "thematic" coding, initial set of codes will be created which will be reviewed by the CAB to ensure they are relevant and complete. The coded transcripts will be analyzed with ATLAS.ti, a qualitative data analysis software.
Baseline Visit, 6 months visit, 12 month visit

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Nadia Islam, NYU Langone

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

20. juli 2020

Primær fullføring (Faktiske)

30. september 2021

Studiet fullført (Faktiske)

30. september 2021

Datoer for studieregistrering

Først innsendt

31. januar 2020

Først innsendt som oppfylte QC-kriteriene

7. februar 2020

Først lagt ut (Faktiske)

10. februar 2020

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

28. april 2022

Siste oppdatering sendt inn som oppfylte QC-kriteriene

20. april 2022

Sist bekreftet

1. april 2022

Mer informasjon

Begreper knyttet til denne studien

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • 19-01192

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).

IPD-delingstidsramme

Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.

Tilgangskriterier for IPD-deling

The investigator who proposed to use the data. Researchers who provide a methodologically sound proposal. Upon reasonable request Requests should be directed to laura.wyatt@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Kliniske studier på Hypertensjon

Kliniske studier på CHW

3
Abonnere